• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Crescent Biopharma, Inc. - Common Stock (NQ:CBIO)

14.83 +1.33 (+9.85%)
Streaming Delayed Price Updated: 11:50 AM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Crescent Biopharma, Inc. - Common Stock

News headline image
Crescent Biopharma Announces Grants of Inducement Awards
March 06, 2026
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
February 26, 2026
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at March Investor Conferences
February 23, 2026
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
February 19, 2026
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
February 18, 2026
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 05, 2026
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
January 30, 2026
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
January 05, 2026
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
December 18, 2025
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
December 04, 2025
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
December 04, 2025
From Crescent Biopharma, Inc.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
November 17, 2025
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 06, 2025
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at November Investor Conferences
November 05, 2025
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
November 04, 2025
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at September Investor Conferences
August 28, 2025
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
July 31, 2025
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
July 08, 2025
From Crescent Biopharma
Via GlobeNewswire
News headline image
CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO
July 21, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIO
December 30, 2022
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
CBIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Catalyst Biosciences, Inc. Is Fair to Shareholders
December 28, 2022
From Halper Sadeh LLC
Via Business Wire
News headline image
JDS1, LLC Terminates Proxy Contest at Catalyst’s 2022 Annual Meeting
August 11, 2022
From JDS1, LLC
Via Business Wire
News headline image
JDS1, LLC Files Definitive Proxy Statement and Sends Letter to Catalyst Stockholders
July 22, 2022
From JDS1, LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap